Work

Lessons From a Negative Clinical Trial: Novel Immunological Targets for COVID-19 and Beyond*

Year: 2022

Type: article

Abstract: 1 Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA 2 Cardiovascular Research Institute, Departments of Medicine and Anesthesia, University of California San Francisco, San Francisco, CA *See also p. 103. Dr. Matthay's institution received funding from Roche-Genentech; he received funding from Cellenkos Pharmaceutical. Dr. Sullivan has disclosed that she does not have any potential conflicts of interest.

Source: Critical Care Medicine

DOI: 10.1097/ccm.0000000000005719

Authors: Kathryn M. Sullivan, Michael A. Matthay

Institutions: University of California, San Francisco, University of California San Francisco Medical Center

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4311738255

FWCI:

Cites: 20

Cited by:

Related to: 10